The long-duration response to levodopa: Phenomenology, potential mechanisms and clinical implications

Parkinsonism and Related Disorders

Volumn 17, Issue 8, 2011, Pages 587-592

  Anderson, Elise ^a   Nutt, John ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

LDR; Levodopa; Long duration response; Parkinson's disease

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE 1 RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; ROPINIROLE;

DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSKINESIA; HUMAN; LEARNING; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PHENOMENOLOGY; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; LEVODOPA; PARKINSON DISEASE; REACTION TIME; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052351842     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.03.014     Document Type: Review

References (50)

1. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967, 276:374-379.
2. Muenter M.D., Tyce G.M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971, 46:231-239.
3. The Parkinson Study Group Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
4. Nutt J.G., Woodward W.R., Carter J.H., Gancher S.T. Effect of long-term therapy on pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol 1992, 49:1123-1130.
5. Nutt J.G., Carter J.H., Van Houten L., Woodward W.R. Short-and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 1997, 42:349-355.
6. Barbato L., Stocchi F., Monge A., Vacca L., Ruggieri S., Nordera G., et al. The long duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol 1997, 20:394-401.
7. Quattrone A., Zappia M., Aguglia U., Branca D., Colao R., Montesanti R., et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995, 38:389-395.
8. Holford N.H., Chan P., Nutt J.G., Kieburtz K., Shoulson I., Parkinson Study Group Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006, 33:281-311.
9. Zappia M., Oliveri R.L., Montesanti R., Rizzo M., Bosco D., Plastino M., et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 1999, 52:763-767.
10. Hauser R.A., Holford N.H. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2002, 17:961-968.
11. Nutt J.G., Carter J.H., Woodward W.R. Long-duration response to levodopa. Neurology 1995, 45:1613-1616.
12. Nutt J.G., Carter J.H., Lea E.S., Sexton G.J. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002, 51:686-693.
13. Ogasahara A., Nishikawa Y., Takahashi M., Wada K., Nakamura Y., Yorifuji S., et al. Dopamine metabolism in the central nervous stem after discontinuation of L-DOPA in patients with Parkinson's disease. J Neurol Sci 1984, 66:151-163.
14. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of parkinsonism - chronic treatment with L-DOPA. N Engl J Med 1969, 280:337-345.
15. Turjanski N., Fernandez W., Lees A.J. The effect of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease. J Neurol Neurosurg Psychiatr 1993, 56:771-775.
16. Zappia M., Colao R., Montesanti R., Rizzo M., Aguglia U., Gambardella A., et al. Long-duration response to levodopa influences the pharmocodynamics of short-duration response in Parkinson's disease. Ann Neurol 1997, 42:245-248.
17. Kempster P.A., Frankel J.P., Stern G.M., Lees A.J. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatr 1990, 53:1004-1007.
18. Nutt J.G., Carter J.H., Woodward W.R. Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects. Neurology 1994, 44:1617-1622.
19. Nutt J.G., Chung K.A., Holford N.H. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 2010, 74:1191-1197.
20. Nutt J.G., Carter J.H. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD. Neurology 2000, 54:247-250.
21. Lee E.A., Lee W.Y., Kim Y.S., Kang U.J. The effects of chronic L-DOPA therapy on pharmacodynamics parameters in a rat model of motor response fluctuations. Exp Neurol 2003, 184:304-312.
22. Kuoppamaki M., Al-Barghouthy G., Jackson M.J., Smith L.A., Quinn N., Jenner P. L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates. J Neural Transm 2007, 11:1147-1153.
23. Ichinose H., Ohye T., Takahashi E., Seki N., Hori T., Segawa M., et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994, 8:236-242.
24. Brooks D.J., Ibanez V., Sawle G.V., Playford E.D., Quinn N., Mathias C.J., et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992, 31:184-192.
25. El Atifi-Borel M., Buggia-Prevot V., Platet N., Benabid A.L., Berger F., Sgambato-Faure V. De novo and long-term L-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat. Neurobiol Dis 2009, 34:340-350.
26. Costa R.M. Plastic corticostriatal circuits for action learning: what's dopamine got to do with it?. Ann N Y Acad Sci 2007, 1104:172-191.
27. Ogura T., Ogata M., Akita H., Jitsuki S., Akiba L., Noda K., et al. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease. Neurosci Res 2005, 51:299-308.
28. Beeler J.A., Cao Z.F., Kheirbek M.A., Ding Y., Koranda J., Murakami M., et al. Dopamine-dependent motor learning: insight into levodopa's long duration response. Ann Neurol 2010, 67:639-647.
29. Darvas M., Palmiter R.D. Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors. Proc Natl Acad Sci U S A 2009, 106:14664-14669.
30. Darvas M., Palmiter R.D. Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition. J Neurosci 2010, 30:1158-1165.
31. Yin H.H., Mulcare S.P., Hilário M.R., Clouse E., Holloway T., Davis M.I., et al. Dynamic reorganization of striatal circuits during the acquisition and consolidation of a skill. Nat Neurosci 2009, 12:333-341.
32. Featherstone R.E., McDonald R.J. Dorsal striatum and stimulus-response learning: lesions of the dorsolateral, but not dorsomedial, striatum impair acquisition of a simple discrimination task. Behav Brain Res 2004, 150:15-23.
33. O'Doherty J., Dayan P., Schultz J., Deichmann R., Friston K., Dolan R.J. Dissociable roles of ventral and dorsal striatum in instrumental conditioning. Science 2004, 304:452-454.
34. Jackson G.M., Jackson S.R., Harrison J., Henderson L., Kennard C. Serial reaction time learning and Parkinson's disease: evidence for a procedural learning deficit. Neuropsychologia 1995, 33:577-593.
35. Krebs H.I., Hogan N., Hening W., Admovich S.V., Poizner H. Procedural motor learning in Parkinson's disease. Exp Brain Res 2001, 141:425-437.
36. Doyon J. Motor sequence learning and movement disorders. Curr Opin Neurol 2008, 21:478-483.
37. Packard M.G., Knowlton B.J. Learning and memory functions of the basal ganglia. Annu Rev Neurosci 2002, 25:563-593.
38. Nieuwboer A., Rochester L., Müncks L., Swinnen S.P. Motor learning in Parkinson's disease: limitations and potential for rehabilitation. Parkinsonism Relat Disord 2009, 15(Suppl. 3):S53-S58.
39. Muslimovic D., Post B., Speelman J.D., Schmand B. Motor procedural leaning in Parkinson's disease. Brain 2007, 130:2887-2897.
40. Seidler R.D., Tuite P., Ashe J. Selective impairments in implicit learning in Parkinson's disease. Brain Res 2007, 1137:107-110.
41. Siegert J.S., Taylor K.D., Weatherall M., Abernethy D.A. Is implicit sequence learning impaired in Parkinson's disease? A meta-analysis. Neuropsychology 2006, 20:490-495.
42. Carbon M., Ma Y., Barnes A., Dhawan V., Chaly T., Ghilardi M.F., et al. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage 2004, 21:1497-1507.
43. Badgaiyan R.D., Fischman A.J., Alpert N.M. Striatal dopamine release in sequential learning. Neuroimage 2007, 38:549-556.
44. Badgaiyan R.D., Fischman A.J., Alpert N.M. Explicit motor memory activates the striatal dopamine system. Neuroreport 2008, 19:409-412.
45. Nakamura T., Ghilardi M.F., Mentis M., Dhawan V., Fukuda M., Hacking A., et al. Functional networks in motor sequence learning: abnormal topographies in Parkinson's disease. Hum Brain Mapp 2001, 12:42-60.
46. Tremblay P.L., Bedard M.A., Langlois D., Blanchet P.J., Lemay M., Parent M. Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson's disease. Exp Brain Res 2010, 2005:375-385.
47. Feigin A., Ghilardi M.F., Carbon M., Edwards C., Fukuda M., Dhawan V., et al. Effects of levodopa on motor sequence learning in Parkinson's disease. Neurology 2003, 60:1744-1749.
48. Fukuda M., Ghilardi M.F., Carbon M., Dhawan V., Ma Y., Feigin A., et al. Pallidal stimulation for parkinsonism: improved brain activation during sequence learning. Ann Neurol 2002, 52:144-152.
49. Dowd E., Dunnett S.B. Movement without dopamine: striatal dopamine is required to maintain but not to perform learned actions. Biochem Soc Trans 2007, 35:428-432.
50. Mayeux R., Stern Y., Mulvey K., Cote L. Reappraisal of temporary levodopa withdrawal (" drug holiday" ) in Parkinson's disease. N Engl J Med 1985, 313:724-728.